All In Biotech

Drug Trial Radar · NCT03713879

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: a Randomized Trial

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,734 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,734

Planned (sponsor's estimate)

Start

Mar 21, 2019

Primary completion

May 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Xijing Hospital; Changhai Hospital; Tianjin Union Medical Center; First Affiliated Hospital of Zhejiang University; Eastern Hepatobiliary Surgery Hospital
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant morbidities and occasional mortalities. The use of rectall administered indomethacin and pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The comparative effectiveness of the two methods has however not been studied. It is argued that in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS insertion however believe that mechanical decompression of the pancreatic duct is critical in the prevention of pancreatitis. The investigators propose a multi-centre randomised controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk patients in the prevention of PEP.

Conditions

  • Post ERCP Pancreatitis

Interventions

  • pancreatic stentingDevice

    a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025" or .035" wire)

  • IndomethacinDrug

    rectally administered indomethacin before or after ERCP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. post-ERCP pancreatitisTime frame: 30 days
  2. high severity of post-ERCP pancreatitisTime frame: 30 days
  3. pancreatitis with complicationsTime frame: 30 days

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Endoscopy centre

    Xi'an, Shaanxi, China · Recruiting

  • Eastern Hepatobiliary Surgery Hospital,Endoscopy centre

    Shanghai, Shanghai Municipality, China · Recruiting

  • Endoscopy centre

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Endoscopy centre

    Tianjin, Tianjin Municipality, China · Recruiting

  • Endoscopy centre

    Hangzhou, Zhejiang, China · Recruiting

  • Endoscopy Centre, Prince of Wales Hospital

    Hong Kong, Hong Kong, Hong Kong · Recruiting

  • 2. Chulalongkorn University and King Chulalongkorn Memorial Hospital

    Bangkok, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.